Paradromics is building a Brain-Computer Interface. Technology that decodes neural activity and translates thought into action. For patients with ALS or paralysis, it's a path back to communication. For regulators, it's uncharted territory: FDA pathways for high-bandwidth BCIs are still being defined.
The science was advancing fast. The documentation couldn't keep up. Operators spent 30 to 60 minutes per process on manual paperwork. Senior engineers devoted a combined 3 to 4 hours every day to reviewing paper travelers. That isn't efficiency drag. It's senior scientific talent being consumed by clerical review when the company's competitive advantage is how fast it can iterate.
Process data lived everywhere and nowhere. Some on paper, some in digital forms, some in legacy systems. When a rework happened and the team needed to find the root cause, the investigation became a scavenger hunt across formats. Traceability. The thing regulators will ultimately demand most of. Was assembled manually when it was needed, not maintained as a system property.
The regulatory stakes are higher here than for most devices. Paradromics isn't iterating on an established device class; they're defining one. Every operational decision compounds: clean data now means a defensible submission later. Messy data now means reconstructing history under audit pressure.



